Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
Clinical trial NCT04956692 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04956692
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-05
- Primary completion
- 2023-04-04
- Enrollment
- 531
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.